Last reviewed · How we verify

Ferrostrane (SODIUM FEREDETATE)

FDA-approved active Small molecule Quality 20/100

Sodium Fedetate (Ferrostrane) is a marketed drug that binds to iron and facilitates its excretion, positioning it in the iron management market. A key strength of Ferrostrane is its established market presence, with a key composition patent expiring in 2028. The primary risk is competition from same-class drugs, including sucroferric oxyhydroxide and ferric maltol, the latter of which is patent-protected until October 23, 2035.

At a glance

Generic nameSODIUM FEREDETATE
Drug classsodium feredetate
ModalitySmall molecule
Therapeutic areaNephrology
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: